Centralized vs. decentralized testing for PD-L1 and HER2 in patients with metastatic gastric and esophageal cancer – Results from the German research platform SAPHIR 25. Oktober 2024 Lordick, F., Bläker, H., Dechow, T., Binninger, A., Ringwald, K., de Buhr, R., von der Heyde, E., Zahn, M.-O., Nusch, A., Dörfel, S., Schulz, H., Lorenzen, S., Reinacher-Schick, A., Haffner I., Jänicke, M., Potthoff, K., 2024. Oncol Res Treat, DGHO-Jahrestagung (Basel) https://doi.org/10.1159/000540557 Abstract Patients with multiple myeloma – What happens in second line after first-line refractory to daratumumab? Data from the German MYRIAM registry Nusch, A., Burkhard-Meier, U., Jacobasch, L., Linde, H., Uhlig, J., Welslau, M., Tech, S., Medinger, T., Jänicke, M., Dechow, T., Einsele, H., Engelhardt, M., Knauf,… Weiterlesen Real-world effectiveness in the total population and in specific subgroups of treatment with palbociclib + endocrine therapy in HR+/HER2- Advanced Breast Cancer (ABC) patients: Interim Results of the PERFORM study Korell M., Pfeiler G., Radosa J., Decker T., Deryal M., Fietz T., Köhler A., Schöttker B., Wilke J., Knoblich J., Petersen V., Dietrich M., Gabrysiak… Weiterlesen